(Total Views: 697)
Posted On: 12/15/2021 9:41:16 PM
Post# of 154185
It said it shot up to $300/share on good phase 2 data. There is also phase 3 data expected before the end of this year 2022 if they are still on time. They expect a price jump to triple again on great news. Current stock price is $74.88 so to over $200/share jump.
Maybe someone can give us a comparison of Leronlimabs top line report to the phase 2 data from this drug resmetirom. The article states that it is the most likely drug to get approved for NASH or NAFLD. Or maybe we can compare to our 350mg open label now?
Maybe someone can give us a comparison of Leronlimabs top line report to the phase 2 data from this drug resmetirom. The article states that it is the most likely drug to get approved for NASH or NAFLD. Or maybe we can compare to our 350mg open label now?
(3)
(0)
